The U.S. administration is reported to be preparing to reclassify marijuana as a less dangerous controlled substance as soon as Wednesday, according to reports citing an official familiar with the matter. That anticipated shift follows an executive order signed in December directing a loosening of federal rules so that marijuana could be moved from Schedule I to Schedule III under the Controlled Substances Act.
The December order asked the attorney general to act promptly to pursue reclassification. If implemented, cannabis would move into a category shared by some commonly prescribed painkillers, ketamine and testosterone - a designation that denotes a lower statutory view of abuse potential and accepted medical use than Schedule I.
What reclassification would mean under existing law
Under current federal law, marijuana is classified as a Schedule I substance, the group that includes drugs judged to carry a high potential for abuse and no accepted medical use. The Department of Health and Human Services carried out a review at the request of the administration and recommended moving marijuana to Schedule III, a category defined as having a moderate to low risk of physical or psychological dependence.
The final decision requires review by the Drug Enforcement Administration (DEA), which must act on the agency recommendation. Until the DEA completes its review and issues a formal reclassification, the statutory and regulatory constraints tied to Schedule I remain in force.
Tax consequences for cannabis businesses
One of the most immediate commercial effects if marijuana is relisted to Schedule III would be the removal of the industry’s exposure to Section 280E of the federal tax code. That provision currently bars businesses trafficking in Schedule I and II substances from claiming standard tax credits and deductions for ordinary business expenses. Eliminating 280E constraints would alter the after-tax economics of many cannabis operators.
Industry access to capital, banking and consolidation
Supporters of reclassification argue it could unlock mainstream banking and draw institutional investment by reducing legal and regulatory friction. At present, many established banks and institutional investors avoid the sector because federal restrictions create compliance risk, leaving cannabis firms to rely on high-cost loans or alternative lenders. A Schedule III designation could make deposit accounts, insurance and other financial services more accessible and could spur mergers and acquisitions as financing becomes easier to obtain.
Congress has separately been considering legislative measures to expand financial access for state-sanctioned cannabis companies. Among them is the Secure and Fair Enforcement Regulation Banking Act (SAFER), introduced in 2023, which is designed to guarantee deposit accounts and related financial services to businesses operating legally under state cannabis laws.
Which companies could be affected
Publicly known cannabis-related firms cited as likely beneficiaries include Canopy Growth, Organigram Global, SNDL, Aurora Cannabis, Trulieve Cannabis and Tilray Brands. A change in federal scheduling could alter cost structures, capital availability and investor appetite for these and other industry participants.
What remains uncertain
Key open questions that will shape long-term outcomes include the size of the addressable market under changed federal policy, how many competitive players will survive or consolidate, the degree of scientific validation for medical use, the regulatory details that accompany any reclassification, and the sustainability of profits should market conditions shift. Until those variables are resolved, valuations and investor interest may remain volatile.
Investors and observers continue to weigh these factors before drawing firm conclusions about the sector’s trajectory.
Promotional note present in prior coverage
Some coverage has included a promotional segment asking whether to invest $2,000 in WEED right now, pointing to an AI-driven tool that evaluates companies using a broad set of financial metrics and noting past winners as examples. That material invited readers to check whether WEED is featured in particular AI strategies and referenced a limited-time sale; such promotional content is separate from the regulatory and market analysis described above.